The company launched the “R2G2” mouse at the American Association for Cancer Research (AACR) annual meeting this week in Washington, DC.
According to the Envigo, the R2G2, a Rag2/IL2RG double knockout model was developed by backcrossing the common gamma chain gene mutation (IL2RG) on to a unique C57BL/6 and 129 mixed background mouse with a mutation in the recombination activating gene 2 (Rag2).
“R2G2 is a triple immunodeficient mouse model on a unique background,” Mike Caulfield, President, North America Operations, Envigo, told Outsourcing-Pharma.com.
“Due to being less radiosensitive, the R2G2 model allows researchers to use a broader range of radiation in their oncology research,” he said.
Additionally, Caulfield explained that because the model is not “leaky” it can be used for longer term studies without interference from the formation of T and B cells.
The company is currently validating the model’s potential humanization benefits and expects to release results in early summer.
The new R2G2 model is part of Envigo’s model sampling program.